TICKERNOMICS Sign up
Last Update: 2023-10-04 11:32:52
Prometheus Biosciences Inc. ( RXDX ) https://www.prometheusbiosciences.com
199.92USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
RXDX
235.61%
SPY
36.71%
RXDX
0.00%
SPY
70.96%
RXDX
0.00%
SPY
262.36%
RXDX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
9488.45
8804.24
1.86
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-68.32
2375.08
13.60
-2.47
0.00
-53.87
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-3720.27
100.00
-4118.45
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.69
-45.53
-33.93
0.00
Other Earnings and Cash Flow Stats:
Prometheus Biosciences Inc. ( RXDX ) Net Income TTM ($MM) is -134.58
Prometheus Biosciences Inc. ( RXDX ) Operating Income TTM ($MM) is -145.56
Prometheus Biosciences Inc. ( RXDX ) Owners' Earnings Annual ($MM) is -134.94
Prometheus Biosciences Inc. ( RXDX ) Current Price to Owners' Earnings ratio is -37.87
Prometheus Biosciences Inc. ( RXDX ) EBITDA TTM ($MM) is -143.48
Prometheus Biosciences Inc. ( RXDX ) EBITDA Margin is -4118.45%
Capital Allocation:
Prometheus Biosciences Inc. ( RXDX ) has paid 0.00 dividends per share and bought back -6.242585 million shares in the past 12 months
Prometheus Biosciences Inc. ( RXDX ) has increased its debt by 0.248 million USD in the last 12 months
Capital Structure:
Prometheus Biosciences Inc. ( RXDX ) Interest-bearing Debt ($MM) as of last quarter is 29
Prometheus Biosciences Inc. ( RXDX ) Annual Working Capital Investments ($MM) are 6
Prometheus Biosciences Inc. ( RXDX ) Book Value ($MM) as of last quarter is 697
Prometheus Biosciences Inc. ( RXDX ) Debt/Capital as of last quarter is 4%
Other Balance Sheet Stats:
Prometheus Biosciences Inc. ( RXDX ) has 113 million in cash on hand as of last quarter
Prometheus Biosciences Inc. ( RXDX ) has 19 million of liabilities due within 12 months, and long term debt 14 as of last quarter
Prometheus Biosciences Inc. ( RXDX ) has 47 common shares outstanding as of last quarter
Prometheus Biosciences Inc. ( RXDX ) has 0 million USD of preferred stock value
Academic Scores:
Prometheus Biosciences Inc. ( RXDX ) Altman Z-Score is 93.36 as of last quarter
Prometheus Biosciences Inc. ( RXDX ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Prometheus Biosciences Inc. ( RXDX ) largest shareholder is FMR Inc owning 1146049 shares at 229.12 ($MM) value
Keith W Marshall(an insider) Sold 10000 shares of Prometheus Biosciences Inc. ( RXDX ) for the amount of $1084200.00 on 2023-04-05
16.61% of Prometheus Biosciences Inc. ( RXDX ) is held by insiders, and 81.01% is held by institutions
Prometheus Biosciences Inc. ( RXDX ) went public on 2021-03-12
Other Prometheus Biosciences Inc. ( RXDX ) financial metrics:
FCF:-124.54
Unlevered Free Cash Flow:-129.04
EPS:-3.25
Operating Margin:-3720.27
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-18.95
Beta:0.00
Buffet's Owners Earnings:-134.94
Price to Owner's Earnings:-37.87
About Prometheus Biosciences Inc. ( RXDX ) :
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.